Navigation Links
Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
Date:7/9/2008

lesterol and coronary artery disease, among others. Research has shown that obesity has a greater impact on the development of chronic conditions in the U.S. than poverty, nicotine or alcohol abuse. Obesity also places a significant financial burden on the economy with mortality and morbidity costs estimated to exceed $100 billion annually.

Empatic combines zonisamide and bupropion, two existing drugs that have been independently approved by the U.S. Food and Drug Administration (FDA) to treat other central nervous system disorders. Orexigen has developed a proprietary sustained release (SR) formulation of zonisamide that has demonstrated a better tolerability profile than the legacy, immediate release (IR) formulation. These two drugs were selected based on their complementary activity in reducing appetite, increasing the body's burning of calories and sustaining weight loss.

The Company's other late-stage obesity product candidate, Contrave(R), is a combination of bupropion SR and naltrexone in a proprietary SR formulation that also appears to result in improved tolerability compared to the legacy naltrexone IR formulation. Contrave currently is being studied in four Phase III clinical trials that are fully enrolled. The program continues on schedule with initial results anticipated in late 2008 or early 2009 and the filing of a New Drug Application (NDA) with the FDA projected for late 2009.

Phase IIb Empatic Trial Details

ZB-202 is a randomized, double-blind, placebo-controlled trial involving approximately 720 generally healthy, nondiabetic obese patients at 20 sites nationwide. The primary endpoint for this trial is percent change in body weight after 24 weeks of blinded therapy. Patients will be randomized to one of six treatment groups including two of the Empatic doses associated with weight loss in the previous Phase IIb trial. The efficacy of Empatic will be compared against zonisamide monotherapy, bupropion monotherapy and pla
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Echo Therapeutics Initiates Clinical Study of Its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
2. Sinovac Initiates Phase II Volunteer Enrollment for Split Viron Pandemic Influenza (H5N1) Vaccine
3. Mpex Initiates a Phase 2 Clinical Trial of Aerosol MP-376 in the Treatment of Chronic Bacterial Infections in Cystic Fibrosis Patients
4. Genmab Initiates Study of Zalutumumab With Radiotherapy in Head and Neck Cancer
5. iCAD Initiates Clinical Study of Its Virtual Colonoscopy CAD in Partnership with ACR Image Metrix
6. Peptimmune Initiates Phase Ib Study of PI-2301 in Multiple Sclerosis Patients and Presentation at BIO 2008
7. Transdel Initiates Ketotransdel(TM) Phase 3 Clinical Program for Pain
8. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
9. TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
10. Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172
11. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  Conkwest, Inc., ... developing the proprietary Natural Killer (NK) cell-line platform, ... Dr. Patrick Soon-Shiong , NantWorks founder, physician ... definitive agreement to purchase approximately $48 million of ... with the investment, he will be named Co-Chairman ...
(Date:12/24/2014)... LONDON , December 24, 2014 /PRNewswire/ ... expected to grow at an average rate of 8.1%. ... and volume. Hip, knee and spine surgeries are the ... emerging economies they have a lower penetration. Increased number ... use of composites. Non-metallic orthopedic devices have gained popularity ...
(Date:12/24/2014)...  Advanced Medical Isotope Corporation ("AMIC") (OTCQB: ADMD), a ... development of brachytherapy devices and medical isotopes for ... has filed a de novo submission ... marketing clearance for its patented Y-90 RadioGel(TM) device ... Drug and Cosmetic Act (the "Act").  ...
Breaking Medicine Technology:Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3
... not always keep hands injury-freeLAS VEGAS, Feb. 27 ... on the rise in recent years, with more than ... Many of those injuries might be prevented with better ... the 2009 Annual Meeting of the American Academy ...
... Fenofibrate treatment reduces,cardiovascular disease (CVD) ... the,composite of cardiovascular death, myocardial infarction, ... patients with type 2 diabetes and,atherogenic ... high triglyceride (2.3,mmol/L-200mg/dL or higher) and ...
Cached Medicine Technology:Experience Not Always the Best Prescription for Snowblowers 2Experience Not Always the Best Prescription for Snowblowers 3Experience Not Always the Best Prescription for Snowblowers 4Diabetes Patients with High Triglycerides and Low HDL Cholesterol Get the Most Benefit From Fenofibrate Treatment: New Data From the FIELD Study 2Diabetes Patients with High Triglycerides and Low HDL Cholesterol Get the Most Benefit From Fenofibrate Treatment: New Data From the FIELD Study 3Diabetes Patients with High Triglycerides and Low HDL Cholesterol Get the Most Benefit From Fenofibrate Treatment: New Data From the FIELD Study 4Diabetes Patients with High Triglycerides and Low HDL Cholesterol Get the Most Benefit From Fenofibrate Treatment: New Data From the FIELD Study 5Diabetes Patients with High Triglycerides and Low HDL Cholesterol Get the Most Benefit From Fenofibrate Treatment: New Data From the FIELD Study 6
(Date:12/24/2014)... TX (PRWEB) December 24, 2014 Connie ... specialist and functional medicine advocate with 30 years of ... trial to evaluate the health benefits of dietary detoxification. ... with new participants following excellent results from test patients ... When asked to explain her interest in conducting the ...
(Date:12/24/2014)... York, New York (PRWEB) December 24, 2014 ... ( http://www.xareltolawsuit2015.com/ ) that allege the blood thinner ... complications has outlined a leadership structure for the ... Order dated December 17th, the Court plans to ... the parties and also plans on appointing a ...
(Date:12/24/2014)... December 25, 2014 BambooIndustry.com a famous ... many years. Today, the company announces its multiple ... special offer on these new products. , Bamboo panel ... bamboo. The multiple layer bamboo panel board features high ... strong and emissions free. The bamboo panel consists of ...
(Date:12/24/2014)... WEDNESDAY, Dec. 24, 2014 (HealthDay News) -- Adults ... higher risk of migraine headaches, suggests a study ... Neurology . "Childhood maltreatment can have long-lasting ... migraine in adulthood," study author Dawn Buse, director ... New York City, said in a journal news ...
(Date:12/24/2014)... Gluten, a protein found predominately in wheat ... intolerance to gluten, causing side effects that can range ... pain and fatigue. For this reason, Diet Doc created ... safe and fast weight loss while teaching patients how ... reaction. These gluten free diet plans combine the healthiest ...
Breaking Medicine News(10 mins):Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 3Health News:Bamboo Flooring Company Bambooindustry.com Introduces Its Multiple Layer Bamboo Panel Board Collection 2Health News:Abuse in Childhood Tied to Migraines in Adulthood 2Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 2Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 3
... release is available in French . , ... Health Centre researchers has passed its first clinical trial with ... each individual patient, and was developed by Dr. J-P. Routy ... Dr. R. Skaly from the Universit de Montral. "This is ...
... ways to enjoy festive feasting , WEDNESDAY, Nov. 25 (HealthDay ... Thanksgiving to New Year,s, but are already stressing about the ... help is at hand. , It,s possible, say nutrition experts, ... 2010 weighing the same as you do today. , ...
... ... News/ EIN News, an online leader in industry news monitoring and ... analysts: H1N1 News Today ( http://h1n1.einnews.com ). , ... epidemic from governments, news outlets and research centers the world over, ...
... Senior doctors from across the globe have come together to ... to mobilise health professionals across the world to help tackle ... be officially launched on Wednesday 25 November 2009 to coincide ... Lancet on the public health impact of strategies to ...
... , ... Americans are afflicted with sinusitis. A clinically proven, minimally invasive technology for treating chronic ... system by Acclarent™ uses a small catheter and balloon to quickly open and expand ... ...
... ... plastic surgeon in Richmond , is launching a new website utilizing the latest ... site incorporates a variety of media platforms to create an interactive web experience that’s ... , ...
Cached Medicine News:Health News:Tailor-made HIV/AIDS treatment closer to reality 2Health News:Holiday Eating Without the Guilt -- or the Pounds 2Health News:Holiday Eating Without the Guilt -- or the Pounds 3Health News:H1N1 News Today Examines the Swine Flu Virus From a Global Perspective; Read the Latest H1N1 Virus Vaccine & Prevention News From EIN News 2Health News:Senior doctors launch global movement to tackle climate change 2Health News:Novel Technology in Treating Chronic Sinus Infections Available at Baptist 2Health News:Novel Technology in Treating Chronic Sinus Infections Available at Baptist 3Health News:Richmond, Virginia Plastic Surgeon Launches State-of-the-Art Breast Surgery Website 2Health News:Richmond, Virginia Plastic Surgeon Launches State-of-the-Art Breast Surgery Website 3Health News:Richmond, Virginia Plastic Surgeon Launches State-of-the-Art Breast Surgery Website 4
... innovative design, the Burton 7500-I refractor delivers ... At Burton, we set out not only ... innovative concept, but to set the industry ... and stringent testing, we devote more resources ...
... year warranty Set one of two memory ... exam!, One touch auto return button, Durable ... colors , Solid-State push button control panel ... transformer. , Electro-Magnetic counter-balanced slit lamp arm ...
Our 2.5v Ophthalmoscope Sets feature high-quality instruments, handles, and cases....
... technological innovation are standard in all ... for Optometry students, the 18335-SDS combines ... Coaxial-Plus Ophthalmoscope, the superior illumination of ... halogen illumination of the Finnoff Transilluminator, ...
Medicine Products: